$ATIP
ATI Physical Therapy, Inc. Stock $atip

$atip Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000181584921000025 Filed on November 17, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2021 Q1
Revenue	$159.0M	$164.0M	$149.1M
YoY Change	6.97%	52.23%
Cost Of Revenue	$132.6M	$248.9M	$124.0M
YoY Change
Gross Profit	$26.41M	$64.15M	$25.11M
YoY Change
Gross Profit Margin	16.61%	39.11%	16.85%
Selling, General & Admin	$30.80M	$26.39M	$24.73M
YoY Change	18.32%	6.45%
% of Gross Profit	116.6%	41.14%	98.46%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$9.095M	$9.052M	$9.619M
YoY Change	-7.52%	-6.85%
% of Gross Profit	34.44%	14.11%	38.3%
Operating Expenses	$30.80M	$26.39M	$24.73M
YoY Change	18.32%	6.45%
Operating Profit	-$516.9M	-$444.3M	-$6.785M
YoY Change	-21034.43%	3154.25%
Interest Expense	-$7.386M	-$41.81M	-$21.40M
YoY Change	-59954.13%
% of Operating Profit
Other Income/Expense, Net	-$52.00K	-$5.626M	-$153.0K
YoY Change	-100.22%	-112.76%
Pretax Income	-$362.1M	-$487.2M	-$28.33M
YoY Change	29499.87%	3118914.08%
Income Tax	-$35.30M	-$19.73M	-$10.50M
% Of Pretax Income
Net Earnings	-$324.7M	-$435.4M	-$19.13M
YoY Change	-268418.18%	-15983.14%	102.7%
Net Earnings / Revenue	-204.18%	-265.41%	-12.83%
Basic Earnings Per Share	-$1.65	-$3.12	-$0.15
Diluted Earnings Per Share	-$1.65	-$3.12	-$0.15
COMMON SHARES
Basic Shares Outstanding	197.0M shares	139.6M shares	128.3M shares
Diluted Shares Outstanding	197.0M shares	139.6M shares	128.3M shares

Balance Sheet

Concept	2021 Q3	2021 Q2	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$66.09M	$90.57M	$162.5K
YoY Change	4409.18%	362176.0%
Cash & Equivalents	$66.09M	$90.57M	$97.68M
Short-Term Investments
Other Short-Term Assets	$12.32M	$7.541M	$347.6K
YoY Change	2473.23%
Inventory
Prepaid Expenses			$347.6K
Receivables	$85.00M	$87.59M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$163.4M	$185.7M	$510.2K
YoY Change	8304.23%	742688.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$134.9M	$134.0M
YoY Change
Goodwill	$603.3M	$910.7M	$1.300B
YoY Change
Intangibles	$411.1M	$611.5M
YoY Change
Long-Term Investments			$345.0M
YoY Change
Other Assets	$1.941M	$1.871M
YoY Change		2120.24%
Total Long-Term Assets	$1.405B	$1.915B	$345.0M
YoY Change	307.23%	2272002.3%
TOTAL ASSETS
Total Short-Term Assets	$163.4M	$185.7M	$510.2K
Total Long-Term Assets	$1.405B	$1.915B	$345.0M
Total Assets	$1.568B	$2.100B	$345.5M
YoY Change	352.05%	1922092.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.02M	$12.26M	$5.508M
YoY Change	610.17%	12168.5%
Accrued Expenses	$98.51M	$101.5M	$49.32K
YoY Change	159433.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.167M	$8.167M
YoY Change
Total Short-Term Liabilities	$125.2M	$128.9M	$5.557M
YoY Change	7657.81%	128926.38%
LONG-TERM LIABILITIES
Long-Term Debt	$545.3M	$546.8M	$0.00
YoY Change
Other Long-Term Liabilities	$7.231M	$7.530M	$32.87M
YoY Change	-40.12%
Total Long-Term Liabilities	$552.5M	$554.3M	$32.87M
YoY Change	4475.69%
TOTAL LIABILITIES
Total Short-Term Liabilities	$125.2M	$128.9M	$5.557M
Total Long-Term Liabilities	$552.5M	$554.3M	$32.87M
Total Liabilities	$1.066B	$1.265B	$38.43M
YoY Change	7689.61%	1265963.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$855.0M	-$523.3M	-$5.809M
YoY Change	68909.58%	3350015.24%
Common Stock	$20.00K	$20.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$495.2M	$825.5M	$5.000M
YoY Change
Total Liabilities & Shareholders Equity	$1.568B	$2.100B	$345.5M
YoY Change	352.05%	1922092.83%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2021 Q1
OPERATING ACTIVITIES
Net Income	-$324.7M	-$435.4M	-$19.13M
YoY Change	-268418.18%	-15983.14%	102.7%
Depreciation, Depletion And Amortization	$9.095M	$9.052M	$9.619M
YoY Change	-7.52%	-6.85%
Cash From Operating Activities	-$11.55M	-$25.93M	-$30.07M
YoY Change	2463.68%
INVESTING ACTIVITIES
Capital Expenditures	-$9.865M	-$19.21M	$8.376M
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$105.0K	$240.1K	$27.90K
YoY Change	-100.03%
Cash From Investing Activities	-$9.760M	-$18.97M	-$8.762M
YoY Change	-97.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net			$2.042M
YoY Change
Cash From Financing Activities	-3.163M	-5.507M	-$5.617M
YoY Change	-100.91%	-22128.0%
NET CHANGE
Cash From Operating Activities	-11.55M	-25.93M	-$30.07M
Cash From Investing Activities	-9.760M	-18.97M	-$8.762M
Cash From Financing Activities	-3.163M	-5.507M	-$5.617M
Net Change In Cash	-24.48M	-50.41M	-$44.45M
YoY Change	-1798.93%	-201732.32%
FREE CASH FLOW
Cash From Operating Activities	-$11.55M	-$25.93M	-$30.07M
Capital Expenditures	-$9.865M	-$19.21M	$8.376M
Free Cash Flow	-$1.689M	-$6.719M	-$38.45M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001815849
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39439
	dei	Entity Registrant Name EntityRegistrantName	ATI Physical Therapy, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1408039
	dei	Entity Address Address Line1 EntityAddressAddressLine1	790 Remington Boulevard
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bolingbrook
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60440
	dei	City Area Code CityAreaCode	630
	dei	Local Phone Number LocalPhoneNumber	296-2223
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	197254406	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66092000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142128000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	56759000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	69693000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	85001000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	90707000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	12317000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6027000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	163410000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	238862000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	134862000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137174000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	253808000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	258227000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	603287000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	1330085000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	411095000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	644339000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1941000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1685000	USD
CY2021Q3	us-gaap	Assets Assets	1568403000	USD
CY2020Q4	us-gaap	Assets Assets	2610372000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	11022000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12148000	USD
CY2021Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	57505000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	70690000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48499000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	52395000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	8167000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8167000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	125193000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	143400000	USD
CY2021Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	53235000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	253990000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7231000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18571000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	545283000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	991418000	USD
CY2021Q3	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent	0	USD
CY2020Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent	163329000	USD
CY2021Q3	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	6512000	USD
CY2020Q4	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2021Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	79882000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	138547000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	248965000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	1066301000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1709255000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207300000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	197300000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	138900000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128300000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1350707000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	954728000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-529000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1907000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-854999000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68804000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	495199000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	884030000	USD
CY2021Q3	us-gaap	Minority Interest MinorityInterest	6903000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	17087000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	502102000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	901117000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1568403000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2610372000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	159013000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148655000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	472108000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	439147000	USD
CY2021Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	86838000	USD
CY2020Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	78039000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	248409000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	227354000	USD
CY2021Q3	ati	Rent Clinic Supplied Contract Labor And Other Operating Expenses RentClinicSuppliedContractLaborAndOtherOperatingExpenses	45765000	USD
CY2020Q3	ati	Rent Clinic Supplied Contract Labor And Other Operating Expenses RentClinicSuppliedContractLaborAndOtherOperatingExpenses	39183000	USD
	ati	Rent Clinic Supplied Contract Labor And Other Operating Expenses RentClinicSuppliedContractLaborAndOtherOperatingExpenses	133140000	USD
	ati	Rent Clinic Supplied Contract Labor And Other Operating Expenses RentClinicSuppliedContractLaborAndOtherOperatingExpenses	123320000	USD
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3514000	USD
CY2020Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2938000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14270000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	12899000	USD
CY2021Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	136117000	USD
CY2020Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	120160000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	395819000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	363573000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30795000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26026000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	81912000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74288000	USD
CY2021Q3	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	508972000	USD
CY2020Q3	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	962303000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20424000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-516871000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2469000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-967926000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1286000	USD
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-15885000	USD
CY2020Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2021Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	146317000	USD
CY2020Q3	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	167265000	USD
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2021Q3	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	0	USD
CY2020Q3	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	0	USD
	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	-14037000	USD
	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	0	USD
CY2021Q3	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-7386000	USD
CY2021Q3	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	0	USD
CY2020Q3	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-17346000	USD
	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-39105000	USD
	ati	Interest Income Expense Nonoperating Net Excluding Redeemable Preferred Stock InterestIncomeExpenseNonoperatingNetExcludingRedeemablePreferredStock	-52887000	USD
CY2020Q3	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	4896000	USD
	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	10087000	USD
	ati	Interest Expense On Redeemable Preferred Stock InterestExpenseOnRedeemablePreferredStock	13877000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-52000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23117000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5831000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	67088000	USD
CY2021Q3	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-362107000	USD
CY2020Q3	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	3344000	USD
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-849297000	USD
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	1610000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28287000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2322000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-58533000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4098000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-333820000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	1022000	USD
	us-gaap	Profit Loss ProfitLoss	-790764000	USD
	us-gaap	Profit Loss ProfitLoss	-2488000	USD
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2109000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	901000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4569000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4086000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-331711000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	121000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-786195000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6574000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.68
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.68
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	196996000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	196996000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128286000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128286000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155197000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155197000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128286000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128286000	shares
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-331711000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	121000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-786195000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6574000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	181000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-1133000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1378000	USD
	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-692000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-331530000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1012000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-784817000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7266000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	901117000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	504000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	561000	USD
CY2021Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	3575000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1309000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-19127000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	880789000	USD
CY2021Q2	ati	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	210105000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	300000000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	128453000	USD
CY2021Q2	ati	Adjustments To Additional Paid In Capital Warrant Liability Recognized In Reverse Recapitalization AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityRecognizedInReverseRecapitalization	26936000	USD
CY2021Q2	ati	Adjustment To Additional Paid In Capital Recognition Of Contingent Shares Liability AdjustmentToAdditionalPaidInCapitalRecognitionOfContingentSharesLiability	220500000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3112000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	636000	USD
CY2021Q2	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	920000	USD
CY2021Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3769000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-435357000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	835613000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1248000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	181000	USD
CY2021Q3	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1120000	USD
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2109000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-331711000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	502102000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	904919000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	494000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	265000	USD
CY2020Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1553000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1330000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-9436000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	895614000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	466000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	176000	USD
CY2020Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1855000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	2741000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	900852000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	473000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-1133000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	901000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	121000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	901214000	USD
	us-gaap	Profit Loss ProfitLoss	-790764000	USD
	us-gaap	Profit Loss ProfitLoss	-2488000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	962303000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27990000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	29628000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14270000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	12899000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-58533000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4087000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	33868000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	33384000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4864000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1433000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2644000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3053000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	6335000	USD
	ati	Increase Decrease In Accrued Interest On Redeemable Preferred Stock IncreaseDecreaseInAccruedInterestOnRedeemablePreferredStock	10087000	USD
	ati	Increase Decrease In Accrued Interest On Redeemable Preferred Stock IncreaseDecreaseInAccruedInterestOnRedeemablePreferredStock	13877000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5534000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	-14037000	USD
	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	0	USD
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-219000	USD
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-383000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20424000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	-167265000	USD
	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8564000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9021000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	6580000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3414000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	269000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-389000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	151000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-552000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-11820000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5127000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-39084000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-31223000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	824000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-512000	USD
	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	-8540000	USD
	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	26732000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	24146000	USD
	ati	Transaction Related Amount Due To Former Owners TransactionRelatedAmountDueToFormerOwners	3611000	USD
	ati	Transaction Related Amount Due To Former Owners TransactionRelatedAmountDueToFormerOwners	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38663000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	139133000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27701000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15688000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1375000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	125000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	125000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	120000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	248000	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28703000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15693000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	454160000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6125000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	68750000	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	68750000	USD
	ati	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	229338000	USD
	ati	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	0	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	59000000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	300000000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	19233000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5615000	USD
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	1553000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8670000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7678000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76036000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	115762000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142128000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38303000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66092000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154065000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1378000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	692000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1733000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1216000	USD
	ati	Warrant Liabilities Recognized Upon The Closing Of The Reverse Recapitalization WarrantLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	26936000	USD
	ati	Warrant Liabilities Recognized Upon The Closing Of The Reverse Recapitalization WarrantLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	0	USD
	ati	Contingent Consideration Common Shares Liabilities Recognized Upon The Closing Of The Reverse Recapitalization ContingentConsiderationCommonSharesLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	220500000	USD
	ati	Contingent Consideration Common Shares Liabilities Recognized Upon The Closing Of The Reverse Recapitalization ContingentConsiderationCommonSharesLiabilitiesRecognizedUponTheClosingOfTheReverseRecapitalization	0	USD
	us-gaap	Stock Issued1 StockIssued1	128453000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	35334000	USD
	us-gaap	Interest Paid Net InterestPaidNet	43075000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	156000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-836000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Overview of the Company<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATI Physical Therapy, Inc., together with its subsidiaries (herein referred to as “we”, “the Company”, “ATI Physical Therapy” and “ATI”), is a nationally recognized healthcare company, specializing in outpatient rehabilitation and adjacent healthcare services. The Company provides outpatient physical therapy services under the name ATI Physical Therapy and, as of September 30, 2021, had 900 clinics (as well as 26 clinics under management service agreements) located in 24 states. The Company offers a variety of services within its clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services. The Company’s direct and indirect wholly-owned subsidiaries include, but are not limited to, Wilco Holdco, Inc., ATI Holdings Acquisition, Inc. and ATI Holdings, LLC.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021 (the “Closing Date”), a Business Combination transaction (the “Business Combination”) was finalized pursuant to the Agreement and Plan of Merger ("Merger Agreement"), dated February 21, 2021 between the operating company, Wilco Holdco, Inc. (“Wilco Holdco”), and Fortress Value Acquisition Corp. II (herein referred to as "FAII" and "FVAC"), a special purpose acquisition company. In connection with the closing of the Business Combination, the Company changed its name from Fortress Value Acquisition Corp. II to ATI Physical Therapy, Inc. The Company’s common stock is listed on the New York Stock Exchange ("NYSE") under the symbol “ATIP.”</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business Combination is accounted for as a reverse recapitalization in accordance with U.S. generally accepted accounting principles ("GAAP"). Under </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this method of accounting, FAII is treated as the acquired company and Wilco Holdco is treated as the acquirer for financial statement reporting and accounting purposes. As a result, the historical operations of Wilco Holdco are deemed to be those of the Company. Therefore, the financial statements included in this report reflect (i) the historical operating results of Wilco Holdco prior to the Business Combination; (ii) the combined results of FAII and Wilco Holdco following the Business Combination on June 16, 2021; (iii) the assets and liabilities of Wilco Holdco at their historical cost; and (iv) the Company’s equity structure for all periods presented. The recapitalization of the number of shares of common stock attributable to the Business Combination is reflected retroactively to the earliest period presented and will be utilized for calculating earnings per share in all prior periods presented. No step-up basis of intangible assets or goodwill was recorded in the Business Combination consistent with the treatment of the transaction as a reverse recapitalization of Wilco Holdco, Inc. Refer to “Note 3 - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” for additional information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 and CARES Act</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus ("COVID-19") pandemic in the United States resulted in changes to our operating environment. We continue to closely monitor the impact of COVID-19 on all aspects of our business, and our priorities remain protecting the health and safety of employees and patients, maximizing the availability of services to satisfy patient needs and preserving the operational and financial stability of our business. While we expect the disruption caused by COVID-19 and resulting impacts to diminish over time, we cannot predict the length of such impacts, and if such impacts continue for an extended period, it could have a continued effect on the Company’s results of operations, financial condition and cash flows, which could be material.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law providing reimbursement, grants, waivers and other funds to assist health care providers during the COVID-19 pandemic. The Company has realized benefits under the CARES Act including, but not limited to, the following: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 2020, the Company received approximately $91.5 million of general distribution payments under the Provider Relief Fund. These payments have been recognized as other income in the consolidated statements of operations throughout 2020 in a manner commensurate with the reporting and eligibility requirements issued by HHS. Based on the terms and conditions of the program, including reporting guidance issued by HHS in 2021, the Company believes that it has met the applicable terms and conditions. This includes, but is not limited to, the fact that the Company’s COVID-19 related expenses and lost revenues for the year ended December 31, 2020 exceeded the amount of funds received. To the extent that reporting requirements and terms and conditions are subsequently modified, it may affect the Company’s ability to comply and ability to retain the funds. The following table summarizes the quarterly recognition of general distribution payments recognized in other expense (income), net in the Company's 2020 statements of operations (in millions):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:0.08pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:18.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.388%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44.3)</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23.1)</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24.1)</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ccecff;padding:0 1pt"/><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(91.5)</span></td><td style="background-color:#ccecff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company applied for and attained approval to receive $26.7 million of Medicare Accelerated and Advance Payment Program ("MAAPP") funds during the quarter ended June 30, 2020. During the nine months ended September 30, 2021, the Company repaid $8.5 million in MAAPP funds. Because the Company has not yet met all required performance obligations or performed the services related to the remaining funds, as of September 30, 2021 and December 31, 2020, $18.2 million and $15.5 million of the funds are recorded in accrued expenses and other liabilities, respectively, and zero and $11.2 million of the funds are recorded in other non-current liabilities, respectively.</span></div><div style="margin-bottom:14pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company elected to defer depositing the employer portion of Social Security taxes for payments due from March 27, 2020 through December 31, 2020, interest-free and penalty-free. Related to these payments, as of September 30, 2021 and December 31, 2020, $5.5 million is included in accrued expenses and other liabilities and $5.5 million is included in other non-current liabilities.</span></div>
CY2021Q3	us-gaap	Number Of Stores NumberOfStores	900	clinic
CY2021Q3	ati	Number Of Stores Under Management Service Agreements NumberOfStoresUnderManagementServiceAgreements	26	clinic
CY2021Q3	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	24	state
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021Q3	ati	Fair Value Disclosure Warrant Liability FairValueDisclosureWarrantLiability	6500000	USD
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-15900000	USD
CY2021Q2	ati	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	136.7
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207300000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	196600000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	34137000	shares
CY2021Q2	ati	Stock Converted Reverse Recapitalization Shares StockConvertedReverseRecapitalizationShares	130300000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	30000000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	12845000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207282000	shares
CY2021Q2	ati	Common Stock Shares Issued Vesting Shares CommonStockSharesIssuedVestingShares	8625000	shares
CY2021Q2	ati	Common Stock Shares Issued Restricted CommonStockSharesIssuedRestricted	2014000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	196643000	shares
CY2021Q2	ati	Fair Value Disclosure Warrant Liability FairValueDisclosureWarrantLiability	26900000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-20400000	USD
CY2021Q2	ati	Cash Acquired Through Reverse Recapitalization CashAcquiredThroughReverseRecapitalization	345036000	USD
CY2021Q2	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	89877000	USD
CY2021Q2	ati	Payments Of Reverse Recapitalization Transaction Costs PaymentsOfReverseRecapitalizationTransactionCosts	25821000	USD
CY2021Q2	ati	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	229338000	USD
CY2021Q2	ati	Reverse Recapitalization Transaction Cost Offset Against Proceeds ReverseRecapitalizationTransactionCostOffsetAgainstProceeds	19233000	USD
CY2021Q2	ati	Proceeds From Reverse Recapitalization Transaction Net Of Transaction Cost ProceedsFromReverseRecapitalizationTransactionNetOfTransactionCost	210105000	USD
CY2021Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	300000000	USD
CY2021Q2	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	59000000	USD
	ati	Reverse Recapitalization Transaction Cost ReverseRecapitalizationTransactionCost	5543000	USD
	ati	Net Increase Decrease In Cash Related To Reverse Recapitalization NetIncreaseDecreaseInCashRelatedToReverseRecapitalization	-2473000	USD
	ati	Reverse Recapitalization Transaction Cost ReverseRecapitalizationTransactionCost	5500000	USD
CY2021Q2	ati	Adjustments To Additional Paid In Capital Recapitalization Transaction Costs AdjustmentsToAdditionalPaidInCapitalRecapitalizationTransactionCosts	19200000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	159013000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148655000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	472108000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	439147000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	1330085000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	1330085000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	726798000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2021Q3	us-gaap	Goodwill Goodwill	603287000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	1330085000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	411095000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	644339000	USD
CY2021Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	433200000	USD
CY2021Q1	us-gaap	Goodwill Goodwill	1300000000	USD
CY2021Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	307400000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	910700000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	910679000	USD
CY2021Q2	us-gaap	Assets Assets	2100284000	USD
CY2021Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	108301000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	1264671000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-523288000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	825481000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	835613000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2100284000	USD
CY2021Q2	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	453331000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-444270000	USD
CY2021Q2	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-458857000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19731000	USD
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-439126000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-435357000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.12
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.12
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	453331000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-451055000	USD
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-487190000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-30246000	USD
	us-gaap	Profit Loss ProfitLoss	-456944000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-454484000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.39
	us-gaap	Profit Loss ProfitLoss	-456944000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	453331000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-30246000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27109000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	323582000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	300081000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	188720000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	162907000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	134862000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137174000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	9095000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	9835000	USD
	us-gaap	Depreciation Depreciation	27711000	USD
	us-gaap	Depreciation Depreciation	29492000	USD
CY2021Q3	ati	Medicare Accelerated And Advance Payment Funds And Deferred Employer Social Security Tax Cares Act Current MedicareAcceleratedAndAdvancePaymentFundsAndDeferredEmployerSocialSecurityTaxCARESActCurrent	23654000	USD
CY2020Q4	ati	Medicare Accelerated And Advance Payment Funds And Deferred Employer Social Security Tax Cares Act Current MedicareAcceleratedAndAdvancePaymentFundsAndDeferredEmployerSocialSecurityTaxCARESActCurrent	21031000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18686000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21387000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3406000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2049000	USD
CY2021Q3	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	2739000	USD
CY2020Q4	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	9635000	USD
CY2021Q3	ati	Revenue Cycle Management Costs Current RevenueCycleManagementCostsCurrent	1321000	USD
CY2020Q4	ati	Revenue Cycle Management Costs Current RevenueCycleManagementCostsCurrent	2469000	USD
CY2021Q3	ati	Accrued Transaction Related Cost Current AccruedTransactionRelatedCostCurrent	207000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	8167000	USD
CY2020Q4	ati	Accrued Transaction Related Cost Current AccruedTransactionRelatedCostCurrent	2547000	USD
CY2021Q3	ati	Transaction Related Amount Due To Former Owners Current TransactionRelatedAmountDueToFormerOwnersCurrent	0	USD
CY2020Q4	ati	Transaction Related Amount Due To Former Owners Current TransactionRelatedAmountDueToFormerOwnersCurrent	3611000	USD
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7492000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	7961000	USD
CY2021Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	57505000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	70690000	USD
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2284000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8933000	USD
CY2021Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1356000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2732000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	553450000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	999585000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2041000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8167000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	545283000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	991418000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5500000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	8167000	USD
CY2021Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	546882000	USD
CY2021Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	557090000	USD
CY2021Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3640000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	553450000	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207300000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	197300000	shares
CY2021Q2	ati	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	136.7
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	55623000	shares
CY2021Q2	ati	Gain Loss On Cash Settlement For Outstanding Preferred Stock GainLossOnCashSettlementForOutstandingPreferredStock	-14000000	USD
CY2021Q3	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent	0	USD
CY2020Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount Noncurrent SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent	163300000	USD
CY2021Q2	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	26936000	USD
CY2021Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4539000	USD
CY2021Q2	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	22397000	USD
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-15885000	USD
CY2021Q3	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	6512000	USD
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
	ati	Class Of Warrant Or Right Exercise Period ClassOfWarrantOrRightExercisePeriod	P30D
	ati	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P5Y
CY2021Q2	ati	Class Of Warrant Or Right Period Warrants Are Not Transferable Assignable Or Salable After Business Combination ClassOfWarrantOrRightPeriodWarrantsAreNotTransferableAssignableOrSalableAfterBusinessCombination	P30D
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28300000	USD
CY2020Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.694
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2300000	USD
CY2021Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.078
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.069
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-58500000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	2.545
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4100000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28300000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-58500000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2300000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4100000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3000000	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	16096000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	15874000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	47822000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	47996000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	4425000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	4537000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	14361000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	13519000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	20521000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	20411000	USD
	us-gaap	Lease Cost LeaseCost	62183000	USD
	us-gaap	Lease Cost LeaseCost	61515000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	48918000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	45625000	USD
	ati	Payments For Lease Terminations PaymentsForLeaseTerminations	4570000	USD
	ati	Payments For Lease Terminations PaymentsForLeaseTerminations	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19370000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11416000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M12D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	6.5
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	6.5
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	15639000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	66396000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	61723000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	54841000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	46081000	USD
CY2021Q3	ati	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	124184000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	368864000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	71400000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	297464000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48499000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	248965000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-333820000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	1022000	USD
	us-gaap	Profit Loss ProfitLoss	-790764000	USD
	us-gaap	Profit Loss ProfitLoss	-2488000	USD
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2109000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	901000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4569000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4086000	USD
CY2021Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0	USD
CY2020Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	12000	USD
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0	USD
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	0	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-331711000	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-331711000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	109000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	109000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-786195000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-786195000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6574000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6574000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	196996000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	196996000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128286000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128286000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	155197000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	155197000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128286000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128286000	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.68
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.68
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11270000	shares
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11270000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares

Files In Submission

Name	View Source	Status
0001815849-21-000025-index-headers.html	Edgar Link	pending
0001815849-21-000025-index.html	Edgar Link	pending
0001815849-21-000025.txt	Edgar Link	pending
0001815849-21-000025-xbrl.zip	Edgar Link	pending
ati-20210930.htm	Edgar Link	pending
ati-20210930.xsd	Edgar Link	pending
ati-20210930_cal.xml	Edgar Link	unprocessable
ati-20210930_def.xml	Edgar Link	unprocessable
ati-20210930_g1.jpg	Edgar Link	pending
ati-20210930_g2.jpg	Edgar Link	pending
ati-20210930_g3.jpg	Edgar Link	pending
ati-20210930_htm.xml	Edgar Link	completed
ati-20210930_lab.xml	Edgar Link	unprocessable
ati-20210930_pre.xml	Edgar Link	unprocessable
exhibit101_q32021xmutualre.htm	Edgar Link	pending
exhibit102_q32021xmutualre.htm	Edgar Link	pending
exhibit311_q32021.htm	Edgar Link	pending
exhibit312_q32021.htm	Edgar Link	pending
exhibit313_q32021.htm	Edgar Link	pending
exhibit32_q32021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATIP
ATI Physical Therapy, Inc. Stock $atip

2021 Q3 Form 10-Q Financial Statement

#000181584921000025 Filed on November 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATIP ATI Physical Therapy, Inc. Stock $atip

2021 Q3 Form 10-Q Financial Statement

#000181584921000025 Filed on November 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATIP
ATI Physical Therapy, Inc. Stock $atip